Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Genzyme, a Sanofi Company
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Primary liver transplant recipient with Model for End-Stage Liver Disease (MELD) criteria documentation
Serum creatinine \> 1.5mg/dL at the time of transplant, or based on the value used to calculate the most recent pre-operative MELD Score for liver allocation
Ages greater than or equal to 18 years
If female, must not be lactating; must have a negative serum beta-human chorionic gonadotropin (HCG) test within 7 days prior to Study Day 0 (Day of Transplant); and must agree to practice an acceptable and reliable form of contraception during the study
Signed informed consent
You may not be if
Living donor or multiple organ transplants
Prior solid organ or bone marrow transplant recipient
Fulminant hepatic failure
Status 1 transplants
ABO incompatible transplants
Transplants utilizing livers from non heart-beating donors
Liver transplant candidates with \> 6 weeks of analysis
Donor with positive serology for hepatitis B surface antigen (HBsAg)
Evidence of human immunodeficiency virus (HIV)
Autoimmune hepatitis
History of chronic steroid or immunosuppressant use in the 90 days prior to transplant, except for inhaled corticosteroids to treat asthma
Recipient of investigational therapy within 90 days prior to transplant procedure
Known contraindication to administration of rabbit anti-thymocyte globulin
Acute viral illness
History of malignancy within 5 years, with the exception of adequately treated localized squamous or basal cell carcinoma of the skin without evidence of recurrence, and/or hepatocellular carcinoma
Illness other than primary liver disease (e.g. severe ischemic heart disease, left ventricular dysfunction, or pulmonary disease), which, in the opinion of the investigator, may significantly increase the risk of the transplantation procedure
Current drug and alcohol abuse that, in the opinion of the investigator, puts subjects at risk for poor compliance (no drug test required)
Clareo Health | Evaluation of Thymoglobulin Induction and Reduced Doses of Calcineurin Inhibitors on Liver Transplant Rejection
